Navigation Links
Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development Status of Pafuramidine and Other in-Licensed Products
Date:12/28/2007

status. At that time, Immtech and the independent experts in liver toxicity will prepare a summary of the available safety data and recommendations for presentation to the FDA. The clinical hold may be released after FDA has received satisfactory data regarding the safety of pafuramidine.

In return for the commercialization rights to pafuramidine, Par paid Immtech an initial payment of $3 million, which Par incurred as Research & Development (R&D) expense in 2007. Should pafuramidine advance through its ongoing Phase III clinical trials and U.S. regulatory review and approval, Par will pay Immtech up to $29 million in development milestones.

Loramyc(R) (miconazole Lauriad(R)) for the treatment of oropharyngeal candidiasis:

In July 2007, Par Pharmaceutical, Inc. entered into an exclusive licensing agreement under which Par received commercialization rights in the U.S. to BioAlliance Pharma's Loramyc(R) (miconazole Lauriad(R)). Loramyc(R) is an innovative antifungal therapy in Phase III development for the treatment of oropharyngeal candidiasis, an opportunistic infection commonly found in immunocompromised patients, including those with HIV and cancer.

Loramyc(R), which received marketing authorization in France in October 2006, is an antifungal delivered in a mucoadhesive buccal tablet, enabling an early and extended release of the active ingredient at the site of infection, with once-daily dosing.

Patient enrollment has been completed in the pivotal Phase III clinical trial intended to support U.S. registration. Trial results are expected in the first half of 2008 and a new drug application is expected to be submitted to FDA in the second half of 2008.

In return for the commercialization rights to Loramyc(R), Par paid BioAlliance an initial payment of $15 million, which Par incurred as R&D expense in 2007. Upon FDA approval of the product, Par will also pay BioAlliance $20 million. In addition to royalties on sales, BioAll
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Introducing Strativa Pharmaceuticals
2. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
3. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
6. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
7. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
8. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
9. Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors
10. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... will hold its 2015 Annual Meeting of Stockholders on ... the expected date for the Annual Meeting represents a ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 ... into law H.R. 83, the Omnibus and Continuing ... first time, made hydrocephalus a condition eligible to ... Programs (CDMRP) administered by the Department of Defense ... with its allies on Capitol Hill, is celebrating ...
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... , , WALTHAM, Mass., Aug. ... and advisory firms focusing on pharmaceutical and healthcare issues, finds ... in second- and third-line therapy since last year,s analysis of ... to the publication of the ENHANCE trial which called into ...
... , , SUNNYVALE, Calif., ... ), a global leader in the field of radiosurgery, today announced ... has purchased a CyberKnife(R) Robotic Radiosurgery System. This marks the seventh ... RoboCouch Patient Positioning System. GNUH is the first national university hospital ...
... China, Aug. 12 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (OTC ... developer, manufacturer and supplier of pharmaceutical,products and medical ... announced that management will hold a conference call ... EDT on Friday, August 14, 2009. Financial,results ...
Cached Biology Technology:Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 2Merck/Schering-Plough's Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Year's Analysis of Dyslipidemia 3Seventh CyberKnife System in South Korea Purchased 2Seventh CyberKnife System in South Korea Purchased 3Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT 2Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT 3
(Date:12/17/2014)... 2014 Research and Markets ( ... "Samsung Galaxy S5 - Home Button Synaptics ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... technology than the iPhone 5S, Samsung introduces for ... product. The Galaxy S5 home button ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences ... monitoring, has released a new series of digital ... preclinical toxicology researchers. M series, part of the ... collect the best possible physiologic data when incorporating ... Adding functional endpoints to toxicology studies has evolved ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... sources, researchers are looking more to plants that grow in ... However, attempts to "domesticate" wild-growing plants have a downside, ... number of plant viruses. In a presentation at this ... Science, Michigan State University plant biologist Carolyn Malmstrom said that ...
... can break down plant biomass into the precursors of biodiesel ... produce alternatives to petroleum. But the potential of this "biorefinery" ... break down lignin, a highly stable polymer that makes up ... Streptomyces bacteria are among few microorganisms known to degrade ...
... The protein structure of the motor that propels archaea ... team of scientists from the U.S. Department of Energy,s ... Planck Institute (MPI) for Terrestrial Microbiology. The ... long been called a flagellum, a whip-like filament that, ...
Cached Biology News:Avoiding virus dangers in 'domesticating' wild plants for biofuel use 2A microbial biorefinery provides new insight into how bacteria regulate genes 2A microbial biorefinery provides new insight into how bacteria regulate genes 3Revealing the secrets of motility in archaea 2Revealing the secrets of motility in archaea 3Revealing the secrets of motility in archaea 4Revealing the secrets of motility in archaea 5
MagSi monodispers, magnetic silica particles with modified surface for SO3 coupling chemistry....
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Rabbit polyclonal to Dishevelled 2 ( Abpromise for all tested applications). entrezGeneID: 1856 SwissProtID: O14641...
... repeat and SOCS box-containing protein) This polyclonal ... amino acids 75-93 and 348-368 of human ... No. 40149) can be used as a ... mouse and rat Asb-2, based on amino ...
Biology Products: